Evercore ISI Group Maintains Outperform on Altimmune, Lowers Price Target to $17

Benzinga Newsdesk www.benzinga.com Negative 95.8%

Neg 95.8% Neu 0% Pos 0%

Evercore ISI Group analyst Liisa Bayko maintains Altimmune (NASDAQ:ALT) with a Outperform and lowers the price target from $18 to $17.